3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
2
Pancreatic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
Cisplatin
5
nimotuzumab
2
X-Rays
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
trifluridine tipiracil drug combination
1
sargramostim
1
palladium-bacteriopheophorbide
1
padeliporfin
1
imgatuzumab
1
galactomannan
1
futuximab
1
fluoromisonidazole
1
capmatinib
1
cabozantinib
1
Tomography, Optical Coherence
1
Standard of Care
1
Specimen Handling
1
Ramucirumab
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Practice Guidelines as Topic
1
Platinum
1
Nivolumab
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Mitomycin
1
LMB-100
1
Ipilimumab
1
Interviews as Topic
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Carcinoma
×
Mitomycin
×
Clear all
NCT04006691
2020-05-07
Retreatment
UroGen Pharma Ltd.
Phase 3
Withdrawn